Topiramate: A Case Series Study in Migraine Prophylaxis

Young, WB; Hopkins, Mary; Shechter, A. L.; Silberstein, SD

doi:10.1046/j.1468-2982.2002.00380.x

Cited by 46 publications

(29 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The third trial (MIGR-003 study), which compared topiramate to propranolol and placebo, has recently been completed but results are still not available. 18 Young et al evaluated the outcome of 74 migraine patients treated with topiramate in a case series study (73). Twenty four patients had episodic migraine and fifty had chronic migraine.…”

mentioning

confidence: 99%

Botulinum Toxin and Other New Approaches to Migraine Therapy

Ashkenazi

Silberstein

2004

Annu. Rev. Med.

View full text Add to dashboard Cite

The number of migraine treatments and our understanding of migraine pathophysiology are both increasing. Newer treatments focus on migraine prevention. Botulinum toxin (BTX) is a potent neurotoxin used primarily to treat diseases associated with increased muscle activity. Recently, BTX was found to have antinociceptive effects that are probably independent of its muscle-relaxant action. Clinical trials support the efficacy of BTX type A (and possibly also type B) in the treatment of migraine. The anticonvulsant topiramate was recently shown to be effective for migraine prevention. At the low doses used for this indication, cognitive side effects are not a major concern. Another new approach to migraine prevention is angiotensin type 1 (AT1) receptor blockade. The high tolerability of the AT1 receptor blocker candesartan warrants further studies to assess its role in migraine prevention.

show abstract

mentioning

confidence: 99%

Botulinum Toxin and Other New Approaches to Migraine Therapy

Ashkenazi

Silberstein

2004

Annu. Rev. Med.

View full text Add to dashboard Cite

show abstract

“…Topiramate is effective in migraine therapy [Mathew et al, 2002;Young et al, 2002;Silberstein, 2005]. Consistent with this, Goadsby and associate showed that topiramate inhibits neurogenic dural vasodilation by inhibiting CGRP release from prejunctional trigeminal neurons.…”

Section: Treatment Of Migraine Headachesmentioning

confidence: 73%

Role of neuropeptides in migraine: where do they stand in the latest expert recommendations in migraine treatment?

Samsam

Coveñas

Ahangari

et al. 2007

Drug Development Research

View full text Add to dashboard Cite

Many factors have been implicated in the pathogenesis of migraine headache, including activation of the trigeminovascular system, dysfunction of: cerebral blood vessels, circulating vasoactive substances, mitochondrial energy metabolism, brain oxygenation and metabolism, platelet disorder, alterations in serotonin levels, low levels of brain tissue magnesium, altered transport of ions across the cell membrane, and inheritance and dysfunction of the brainstem periaqueductal gray matter. The headache phase of migraine is associated with cerebral vasodilation and inflammation, presumably mediated by the release of vasoactive substances and neuropeptides including CGRP (calcitonin gene-related peptide). Increased serum CGRP levels have been detected during migraine and cluster headache. One strategy to treat migraine is to inhibit the release of neuropeptides or to block their receptors. This article briefly reviews some experimental and clinical investigations focused on neuropeptide involvement in migraine. Drug Dev Res 68: 294-314, 2007.

show abstract

“…Topiramate has demonstrated efficacy for the treatment of migraine in open-label (Hershey et al, 2002;Mathew et al, 2002;Von Seggern et al, 2002;Young et al, 2002), and double-blind trials (Storey et al, 2001;Brandes et al, 2003;Dodick et al, 2003;Rothrock et al, 2003), significantly decreasing the frequency and severity of migraine, and the need for abortive medications. In a doubleblind trial in 40 patients, topiramate significantly reduced migraine frequency compared with placebo (36% vs 14%) (Storey et al, 2001).…”

Section: Migraine and Pain Syndromesmentioning

confidence: 99%

Comorbidity in bipolar disorder: a framework for rational treatment selection

McIntyre

Konarski

Yatham

2004

Human Psychopharmacology

View full text Add to dashboard Cite

Bipolar disorders are heterogeneous disorders often requiring multimodality treatment. The expanding pharmacopeia for bipolar disorders invites the need for a treatment framework that both recognizes and anticipates the multidimensionality and comorbidity of the illness. No available neurotherapeutic agent is singularly efficacious for the complete mélange of bipolar symptomatology. An apparent paradox has emerged in the management of bipolar disorder; whilst results from rigorous controlled monotherapy trials suggest that a disparate assortment of neurotherapeutic agents are efficacious in distinct phases of bipolar disorder, the majority of tertiary-treated bipolar patients receive polypharmacotherapeutic regimens. The evidentiary base for polypharmacotherapy is sparse and has recently become an area of active research focus. In the interim, clinicians are encouraged to invoke an organizational schema for the treatment of bipolar disorder that considers the spectrum of effectiveness of putative and established mood stabilizers. This schema should be further informed by the treatment data for comorbid and accessory conditions. The authors propose a schema to provide the impetus for further work in the area.

show abstract

Topiramate: A Case Series Study in Migraine Prophylaxis

Cited by 46 publications

References 13 publications

Botulinum Toxin and Other New Approaches to Migraine Therapy

Botulinum Toxin and Other New Approaches to Migraine Therapy

Role of neuropeptides in migraine: where do they stand in the latest expert recommendations in migraine treatment?

Comorbidity in bipolar disorder: a framework for rational treatment selection

Contact Info

Product

Resources

About